Is a biologic knee injection right for my knee now

Knee injections made from a person’s own blood or tissue are usually discussed when knee arthritis symptoms are becoming limiting, but an X‑ray still shows some joint space and the knee is not yet “bone-on-bone”. In that early-to-moderate stage, the goal is typically symptom control (pain, swelling and stiffness) and steadier day‑to‑day function, rather than a guaranteed structural “fix”.

PRP, microfragmented adipose tissue (mFAT, often described as Lipogems‑type), and bone marrow aspirate concentrate (BMAC) are all autologous orthobiologics used as outpatient, ultrasound‑guided knee injections. They are intended to support the knee’s own repair processes and modulate inflammation; they are not instant cures and published studies do not justify promises of cartilage regrowth. Even when they help, they may delay—but do not reliably prevent—knee replacement in more advanced arthritis.

These injections are generally positioned on top of core knee osteoarthritis care: education, weight optimisation where relevant, progressive strengthening and movement therapy, and simple analgesia as needed.

Evidence strength also differs between options. PRP has the largest knee‑specific trial and meta‑analysis base, with placebo‑controlled studies showing meaningful average improvements in pain and function in many patients over follow‑up periods up to 12 months. Comparative analyses often rank PRP highly among injectables at 6 months or more. BMAC evidence is emerging, including randomised trials showing within‑group improvement and small statistical advantages over hyaluronic acid that may not reach clinically important thresholds. For adipose-based injections, a blinded 120‑patient trial with 2‑year follow‑up found single‑dose mFAT was not superior to saline placebo for knee symptoms.

What to expect from PRP knee injections

On the day, PRP is usually a straightforward outpatient pathway: a small blood sample is taken, processed in a centrifuge to concentrate platelets in plasma, and the PRP is then placed into the knee joint (often with ultrasound guidance for accurate positioning). Because PRP relies on a controlled healing response, it is common for people to leave the clinic the same day but feel that the knee is “more irritated” for a short period afterwards.

Course and spacing

Most knee PRP protocols use a short course rather than an open-ended run of injections, commonly 1–3 injections spaced roughly 1–4 weeks apart.

Aftercare and recovery

A brief flare of soreness and swelling in the first few days is commonly described after knee PRP. Medication planning (for example, whether to pause anti-inflammatory medicines around treatment) is usually handled case-by-case by the treating clinician.

A practical timeline (week 0 to 12 months)

In trials, measurable changes are often assessed at 6 weeks, 3 months, 6 months, and 12 months. A 2025 meta-analysis (18 RCTs; 1,995 patients) found PRP improved pain and WOMAC function versus placebo at 1, 3, 6, and 12 months, with clinically meaningful improvements at key time points for many patients.

How PRP compares with steroid and other injectables

Across randomised trials, corticosteroid injections often help quickly but tend to fade sooner, whereas PRP results are frequently more sustained at later follow-ups (up to 12 months in several studies). In a 2024 network meta-analysis of 48 RCTs with at least 6-month follow-up, PRP had the highest probability of the greatest pain and function improvement, with BMAC and hyaluronic acid ranking behind it and corticosteroid close to placebo.

Taken together, PRP for knee osteoarthritis is often delivered as a short series (commonly up to three injections) with a few days of post-injection irritability, improvement that typically declares itself over 6–12 weeks, and benefits that may last up to 12 months in a substantial proportion—after which some people consider repeating the course, depending on symptoms and knee stage.

Using your own knee fat (mFAT) for pain relief

mFAT (microfragmented adipose tissue, often described as a Lipogems-type treatment) is usually positioned as a “use your own fat as a biological support injection” for an arthritic knee. This section summarises the main knee studies without the raw in-text source strings that can appear in earlier drafts; the supporting papers are intended to sit in a separate references list.

In a typical outpatient pathway, a small amount of fat is taken from just under the skin (commonly from the abdomen or upper thigh) using needle-based techniques and local anaesthetic, then mechanically washed and gently broken into tiny clusters. The processed mFAT is then placed into the knee joint under ultrasound guidance in the same appointment. Because there is a harvest step, it is common for the most noticeable after-effects to be bruising and tenderness at the harvest site for several days, alongside the sort of short-lived “flare” (soreness and swelling) that can happen after many knee injections.

The intended effect is not a mechanical “lubricant” like hyaluronic acid, and it is not proven cartilage rebuilding in established knee osteoarthritis. The rationale described in reviews is that the microfragmented tissue retains a supportive cell environment and extracellular matrix that may release anti-inflammatory and trophic signals inside the joint, potentially helping symptoms in some people.

The strongest placebo-controlled evidence to date is sobering. A blinded randomised controlled trial in 120 patients with Kellgren–Lawrence grade 2–3 knee osteoarthritis compared a single mFAT injection with saline and found no meaningful difference in KOOS4 or other outcomes at 6, 12, or 24 months—even though both groups improved from baseline. In other words, the study supports that a single-shot mFAT approach appears safe, but it does not allow confidence that mFAT adds benefit beyond placebo for typical symptomatic knee OA.

Other adipose-based knee studies can look more encouraging, but they are harder to interpret. Examples include:

• A retrospective single-centre cohort (72 knees) comparing mFAT with stromal vascular fraction (SVF) reporting improvements in pain and KOOS, with limited between-group differences and no serious adverse events.
• A prospective series combining arthroscopic debridement plus mFAT with follow-up reported out to 48 months, where the lack of a non-operative control makes it impossible to separate any benefit of mFAT from the effect of arthroscopy.
• A 2019–2024 systematic review (452 KL II–III knees) reporting generally sustained improvements up to 24 months, while noting substantial heterogeneity and frequent absence of proper placebo controls.

Taken together, mFAT for knee arthritis sits in a more uncertain evidence position than PRP and (based on current RCTs) does not have the same level of placebo-controlled support as first-line autologous injection options; it is therefore often reserved for selected scenarios, clinician preference, or research-aligned pathways rather than being a default starting point for early knee OA.

Using bone marrow (BMAC) injections for early knee arthritis

Bone marrow aspirate concentrate (BMAC) is an “own‑tissue” knee injection where a small amount of marrow is drawn with a needle (often from the pelvic crest or the top of the shin) under local anaesthetic, processed in a centrifuge to concentrate the cell‑rich fraction and signalling proteins, and then injected into the knee joint under ultrasound guidance in the same outpatient visit. For readability, this section keeps studies and reference IDs out of the running text (they can sit in a references list), rather than showing bracketed tags within paragraphs.

What BMAC is trying to do in an arthritic knee

In knee osteoarthritis, BMAC is generally used to support the body’s own repair processes and modulate inflammation inside the joint, rather than to “replace” worn cartilage or reverse established arthritis. In practical terms, it is closer to a biologic “signal” injection than a mechanical “lubricant” injection.

What the randomised evidence suggests (1–12 months)

A 2024 systematic review of 8 randomised controlled trials (937 patients) reported that people receiving intra‑articular BMAC typically showed meaningful within‑group improvements in knee pain and function from about 1 month onwards. When BMAC was compared with hyaluronic acid (HA), pain scores were statistically better with BMAC at 6 and 12 months, but the size of the difference did not consistently reach commonly used minimal clinically important difference (MCID) thresholds—so the average “edge” over HA may be real but modest.

How BMAC compares with PRP and HA in a 12‑month clinic study

In a single‑centre comparative study of 175 knees with Kellgren–Lawrence grade II–IV osteoarthritis, BMAC, PRP and HA were each associated with improvements in WOMAC and quality‑of‑life measures over 12 months. BMAC showed the largest gains in some physical functioning and mobility domains, and PRP generally outperformed HA, but the study did not include a placebo group and the results may reflect centre‑specific preparation and injection protocols.

Durability beyond a year (what is known, and what is not)

Longer follow‑up data exist mainly as observational series rather than placebo‑controlled trials. For example, a 4‑year prospective series in 37 osteoarthritic knees reported sustained improvements on knee outcome scores and a low rate of conversion to arthroplasty during follow‑up; however, because there was no untreated comparison group, this kind of study cannot prove that BMAC itself delayed knee replacement.

Practical recovery and safety signals

Across published knee studies, serious BMAC‑specific complications are reported as rare, with the most common downside being temporary soreness at the harvest site (for example, the iliac crest area) as well as the typical short‑lived post‑injection flare seen after many intra‑articular knee injections.

A pragmatic way to place BMAC in a knee arthritis pathway is: compared with HA, the average advantage looks small at 6–12 months in randomised data; compared with PRP, BMAC often appeals to people seeking a marrow‑derived autologous option, but clear superiority over other injectables has not been firmly established and protocol differences remain a major source of uncertainty.

PRP vs mFAT vs BMAC for the knee which is stronger

Direct, high-quality “head-to-head” comparisons in early knee osteoarthritis are still rare: there are no robust randomised trials that put PRP, mFAT and BMAC into the same study and follow people for a year or more. Most of what is known comes from separate placebo-controlled trials (for PRP and adipose-derived options) plus a 12‑month single-centre comparison of BMAC vs PRP vs hyaluronic acid (HA) that did not include a placebo arm; in this section the evidence is therefore summarised in plain study terms (for example “2024 network meta-analysis”) rather than in-text reference codes.

Evidence strength (what stands up best when tested)

Across published placebo-controlled knee trials, PRP currently has the strongest overall support. A 2025 meta-analysis of 18 randomised trials (1,995 patients) reported clinically meaningful improvements in pain and WOMAC function versus placebo through 12 months.

For BMAC, randomised evidence is developing rather than definitive. A 2024 systematic review of 8 RCTs (937 patients) reported clear within-group improvements from around 1 month onwards, and small statistical advantages over HA at 6 and 12 months, although the average between-group differences did not consistently reach common MCID thresholds.

For mFAT (Lipogems-type) and related adipose-cell approaches, the most reliable knee data are currently negative against placebo when delivered as a single injection. A blinded RCT in 120 people with KL 2–3 knee OA found no meaningful difference between a single mFAT injection and saline at 6, 12, or 24 months, and the ADIPOA2 phase 2b trial of a single dose of adipose-derived stromal cells (2×10^6 or 10×10^6) also did not outperform saline through 12 months.

One useful “big picture” signal comes from a 2024 network meta-analysis of 48 randomised trials (≥6‑month follow-up): PRP had the highest probability of being best for pain and function (SUCRA ~91.5), with BMAC often next (~76.5), while corticosteroid ranked close to placebo. Adipose treatments are not consistently favoured when the evidence base is restricted to higher-quality randomised data.

Practical differences (what is actually involved)

The main day‑to‑day distinction is the harvest step. PRP typically involves a blood draw only and is often given as a short 1–3 injection course across a few weeks. mFAT and BMAC are usually designed as a single-session pathway: mFAT adds a small-volume fat harvest (commonly abdomen or thigh in clinical practice) and BMAC adds a bone marrow harvest (often iliac crest or proximal tibia), so “down-time” is often more about temporary donor-site bruising or soreness than the knee itself.

Likely benefit and duration (broad expectations, not guarantees)

In published knee studies, many PRP and BMAC patients report meaningful symptom improvement that becomes apparent over the first weeks to months and is still present at 6–12 months in a substantial proportion. For BMAC, some longer-follow-up observational work describes durability beyond 1 year in certain cohorts, but these designs cannot prove that BMAC itself is the reason symptoms stayed improved.

For mFAT, the best placebo-controlled knee evidence shows no extra improvement versus saline out to 24 months after a single injection, so any confident claims about “how long it lasts” are currently hard to justify outside carefully selected scenarios or research-aligned pathways.

A pragmatic “best fit” snapshot for early knee OA

When choosing today, the decision often comes down to a trade-off between evidence strength and tolerance for a harvest procedure:

• PRP: often the first autologous option when the priority is the strongest placebo-controlled knee evidence and avoiding a donor site; protocols commonly use 1–3 injections with follow-up measured at 6–12 months.
• BMAC: sometimes chosen when a one-off, marrow-derived option is preferred and the additional harvest discomfort is acceptable; RCTs suggest improvement is likely, but the “edge” over HA can be modest on average.
• mFAT: usually the least certain choice on current RCT data (including a 120‑patient placebo-controlled trial), so it tends to be reserved for more specific circumstances rather than a default starting point.

All three options are typically self-funded in the UK and sit alongside ongoing knee-specific rehabilitation (strength, movement capacity, and weight optimisation), because even with a good 12‑month response, osteoarthritis remains a long-term condition to manage rather than a one-off fix.

How Lincolnshire Knee helps you decide on injection options

Choosing between PRP, BMAC and mFAT tends to come down to two things established at the start of a consultation: what stage the knee arthritis is at, and what the person is trying to achieve over the next 6–12 months. To keep the close consistent with the evidence-led tone above, the emphasis here stays on the decision steps, with booking details kept to a single line at the end.

At Lincolnshire Knee, the typical first appointment in Sleaford (NG34) or Grantham (NG31) focuses on diagnosis and staging: a detailed symptom history (for example, swelling episodes over the last 12 months), a focused knee examination, and a review of any recent X‑rays or MRI. Where it adds useful detail, objective tools such as MAI Motion® (movement/gait measures) and onMRI™ (knee MRI analysis including cartilage/meniscus mapping) can be used to clarify whether pain is mainly patellofemoral, medial compartment, meniscal, or more generalised.

Before any biologic is suggested, the consultant will usually confirm key “mechanical” factors that drive symptoms in real knees—especially limb alignment and compartment loading—and document what has already been tried (structured physiotherapy, weight change, simple analgesia, and any previous injections). This matters because the same injection can behave very differently in a varus-loaded medial-compartment knee versus a well-aligned knee at a similar Kellgren–Lawrence grade.

Evidence is then folded into the discussion in a practical order. Based on current knee RCT and meta-analysis signals (including 2024–2025 summaries), PRP is commonly the first autologous injection discussed for suitable early-to-moderate OA; BMAC is usually reserved for selected patients who accept the additional marrow-harvest step alongside still-evolving comparative evidence; and mFAT is framed more cautiously given negative placebo-controlled findings for single-injection protocols out to 24 months.

Non-injection routes are also kept on the table at the same time—optimised rehabilitation, bracing and activity modification, and (where alignment or severity warrants it) knee preservation surgery such as osteotomy or, later, partial/total knee replacement—so injections are not presented as the only pathway. When an injection is chosen, it is delivered as an ultrasound-guided outpatient appointment, with follow-up planned to track response and guide rehabilitation over the next 6–12 months.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral; appointments are available without NHS-style waiting lists. Book an assessment at lincolnshireknee.co.uk.

1. [1] Quality of life changes in patients suffering from knee osteoarthritis treated with bone marrow aspirate concentrate, platelet-rich plasma and hyaluronic acid injections. (2025). https://doi.org/10.1080/17460751.2025.2472589 https://doi.org/10.1080/17460751.2025.2472589
2. [2] Platelet rich plasma, bone marrow aspirate concentrate and hyaluronic acid injections outperform corticosteroids in pain and function scores at a minimum of 6 months as intra-articular injections for knee osteoarthritis: A systematic review and network meta-analysis. (2024). https://doi.org/10.1016/j.arthro.2024.01.037 https://doi.org/10.1016/j.arthro.2024.01.037
3. [3] Bone marrow aspirate concentrate (BMAC) for knee osteoarthritis: A narrative review of clinical efficacy and future directions. (2025). https://doi.org/10.3390/medicina61050853 https://doi.org/10.3390/medicina61050853
4. [4] PRP injections for the treatment of knee osteoarthritis: The improvement is clinically significant and influenced by platelet concentration: A meta-analysis of randomized controlled trials. (2025). https://doi.org/10.1177/03635465241246524 https://doi.org/10.1177/03635465241246524
5. [5] Treatment of knee osteoarthritis with a single injection of autologous micro-fragmented adipose tissue is not superior to a placebo saline injection: A blinded randomised controlled trial with 2-year follow-up. (2025). https://doi.org/10.1136/bjsports-2024-108732 https://doi.org/10.1136/bjsports-2024-108732
6. [6] Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees. (2024). https://doi.org/10.1038/s41598-024-51410-2 https://doi.org/10.1038/s41598-024-51410-2